Published: Aug, 2018

TMR observes global chlamydia infection diagnostics and therapeutics market is fairly consolidated due to presence of strong players. The top five players operating the diagnostics accounts for the larger share of nearly equal to 58% while players operating in the therapeutics accounts for nearly 24%. There are numerous companies are operating in the market, however, some of the companies are experiencing fierce competition among them. Some of the key players operating in the global chlamydia infection diagnostics and therapeutics market are Novartis AG, Bio Rad laboratories, F Hoffmann-La Roche, Danaher, Abbott Laboratories, bioMerieux, Siemens AG, Thermo Fisher Scientific, DiaSorin SpA, and Becton Dickinson and Company. In order to be a part of competition, these companies are increasingly focusing on the new product launch, expansion of business across regions, and improving product portfolio. For this, they are adopting the strategies including the acquisitions, mergers, and collaborations.

The global revenue of the chlamydia infection diagnostics and therapeutics market registered at a US$1,195.5 mn in 2016 and is estimated to rise at a CAGR of 6.0% over the forecast period from 2017 to 2025 to attain value of US$2,002.2 mn in 2025. On the basis of diagnostics methods, the market is the segment of nucleic acid amplification tests (NAAT) accounted for the larger share with more than 69.8% in 2016. These tests are approved by FDA and their demand for these sensitive diagnostic tests is fuelled by the rising prevalence of chlamydia. On the basis of region, North America accounted for the larger share of more than 55.5% in 2016.

chlamydia infection dignostics therapeutics market

Demand for Novel Diagnostics and Therapeutics to Boost Growth

Prevalence of chlamydia infection, sexually transmitted diseases (STDs) and numerous other infections are increasing which is boosting need for the novel diagnostics and therapeutics especially in the developed countries is driving demand for infection diagnostics and propelling growth of the global chlamydia infection diagnosis and therapeutics market. Growing number of research and development activities mainly for the academic research is driving growth of the global chlamydia infection diagnosis and therapeutics market.

In addition, rising health awareness coupled with rising healthcare expenditure globally have boosted the demand for chlamydia infection diagnosis and therapeutics. Risk of infection among young generation due to numerous biological factors is fuelling demand for the infection diagnostics which is likely to drive growth of the global chlamydia infection diagnostics and therapeutics market. Availability of sensitive and effective diagnostic tests is leading to surge in the number of cases of these infection.

Advancements in Chlamydia Screening to Create Lucrative Opportunities

However, social shame related to screening of Chlamydia trachomatis which causes Chlamydia is promoting bullying and ostracism, which has discouraged young generation mainly from age group of 16 to 25 who are sexually active to undergo voluntary screening. This factor is restraining growth of the global chlamydia infection diagnostics and therapeutics market. Nevertheless, the factors such as prevalence of co-morbidity factors in women coupled with advancements in the screenings have boosted demand for the infection therapeutics and diagnostics.

This information is comprised in the new report by TMR, titled “Chlamydia Infection Diagnostics and Therapeutics Market (Product Type - Diagnostics (Nucleic Acid Amplification Tests (NAATs) and Direct Fluorescent Tests) and Therapeutics (Macrolides, Quinolones, Sulfonamides, Tetracycline, and Aminopenicillins); End Users - Hospitals, Specialty Clinics, Diagnostic Centers Therapeutics, Hospital Pharmacies, Drugstores, Retail Pharmacies, and Online Pharmacies) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2017 - 2025.

The global chlamydia infection diagnostics and therapeutics market has been segmented as presented:

By Product Type:

  • Diagnostics
    • Nucleic Acid Amplification Tests (NAATs)
    • Direct Fluorescent Tests
  • Therapeutics
    • Macrolides
    • Quinolones
    • Sulfonamides
    • Tetracycline
    • Aminopenicillins

By End Users:

  • Hospitals
  • Specialty Clinics
  • Diagnostic Centers Therapeutics
  • Hospital Pharmacies
  • Drugstores
  • Retail Pharmacies
  • Online Pharmacies

By Geography

  • North America
    • U.S.
    • Canada
  • Europe
    • U.K.
    • Germany
    • France
    • Spain
    • Italy
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • Australia
    • India
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • Rest of Middle East & Africa

About Us

Transparency Market Research is a next-generation market intelligence provider, offering fact-based solutions to business leaders, consultants, and strategy professionals.

Our reports are single-point solutions for businesses to grow, evolve, and mature. Our real-time data collection methods along with ability to track more than one million high growth niche products are aligned with your aims. The detailed and proprietary statistical models used by our analysts offer insights for making right decision in the shortest span of time. For organizations that require specific but comprehensive information we offer customized solutions through adhoc reports. These requests are delivered with the perfect combination of right sense of fact-oriented problem solving methodologies and leveraging existing data repositories.

TMR believes that unison of solutions for clients-specific problems with right methodology of research is the key to help enterprises reach right decision.

Contact Us

Transparency Market Research
State Tower,
90 State Street,
Suite 700,
Albany NY - 12207
United States
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com 
Website: https://www.transparencymarketresearch.com 

.